Gain Therapeutics, Inc. (GANX)Healthcare | Biotechnology | Bethesda, United States | NasdaqGM
1.78 USD
+0.02
(1.136%)
⇧
(July 14, 2026, 9:55 a.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:34 a.m. EDT
The narrative here is a classic biotech trap: dazzling headlines masking a broken business model. While the FDA clearance for the Parkinson's trial is a genuine catalyst, the market has already priced in a catastrophic failure over the last four years, evidenced by an 83% cumulative decline. The company is burning cash aggressively with negative free cash flow and no path to profitability, relying entirely on capital markets to stay alive. The options market confirms this skepticism, with investors stacking put protection at strikes significantly below the current price, expecting further erosion rather than a recovery. Despite the 'strong buy' analyst ratings which likely reflect binary event bets rather than sustainable value, the fundamental reality is a company with no earnings, no dividends, and a precarious balance sheet. The recent price action shows some resilience, but without a proven product or revenue stream, this is a speculative gamble, not an investment. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.052894 |
| AutoETS | 0.061885 |
| AutoARIMA | 0.061964 |
| MSTL | 0.062952 |
| MSTL_90 | 0.081308 |
| MSTL_48_90 | 0.086284 |
| MSTL_48 | 0.094646 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.72 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.756 |
| Excess Kurtosis | -0.37 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.8 |
| Market Cap | 75,924,192 |
| Forward P/E | -2.97 |
| Beta | 0.16 |
| Website | https://gaintherapeutics.com |
As of July 11, 2026, 6:34 a.m. EDT: Speculators are positioning heavily for downside protection, with massive open interest in out-of-the-money puts (strikes 1.5 and 2.0) expiring in August, while call activity remains thin and concentrated near the money. This asymmetry suggests a 'long gamma' environment where traders expect volatility but are betting on a continued grind lower rather than a sharp rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.035294175 |
| Address1 | 4,800 Montgomery Lane |
| Address2 | Suite 220 |
| All Time High | 17.93 |
| All Time Low | 0.89 |
| Ask | 2.27 |
| Ask Size | 2 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 2,277,310 |
| Average Daily Volume3 Month | 865,445 |
| Average Volume | 865,445 |
| Average Volume10Days | 2,277,310 |
| Beta | 0.157 |
| Bid | 1.27 |
| Bid Size | 2 |
| Book Value | 0.33 |
| City | Bethesda |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.78 |
| Current Ratio | 4.688 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.8 |
| Day Low | 1.765 |
| Debt To Equity | 4.8 |
| Display Name | Gain Therapeutics |
| Earnings Timestamp End | 1,754,915,400 |
| Earnings Timestamp Start | 1,754,483,400 |
| Ebitda | -19,666,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.01 |
| Enterprise Value | 59,204,188 |
| Eps Current Year | -0.6025 |
| Eps Forward | -0.6 |
| Eps Trailing Twelve Months | -0.57 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.8056 |
| Fifty Day Average Change | -0.025600076 |
| Fifty Day Average Change Percent | -0.014178154 |
| Fifty Two Week Change Percent | 3.5294175 |
| Fifty Two Week High | 4.34 |
| Fifty Two Week High Change | -2.5600002 |
| Fifty Two Week High Change Percent | -0.58986175 |
| Fifty Two Week Low | 1.41 |
| Fifty Two Week Low Change | 0.37 |
| Fifty Two Week Low Change Percent | 0.26241136 |
| Fifty Two Week Range | 1.41 - 4.34 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,616,160,600,000 |
| Float Shares | 41,645,270 |
| Forward Eps | -0.6 |
| Forward P E | -2.9666665 |
| Free Cashflow | -11,135,494 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 20 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -10,591,801 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02286 |
| Held Percent Institutions | 0.19240999 |
| Implied Shares Outstanding | 42,654,038 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-03-18 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland. |
| Long Name | Gain Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 75,924,192 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_554488027 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -21,239,772 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 74,644,566 |
| Number Of Analyst Opinions | 5 |
| Open | 1.78 |
| Operating Cashflow | -19,371,432 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 301 500 1556 |
| Previous Close | 1.76 |
| Price Eps Current Year | -2.9543567 |
| Price Hint | 4 |
| Price To Book | 5.393939 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.511 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.2 |
| Region | US |
| Regular Market Change | 0.01999998 |
| Regular Market Change Percent | 1.1363626 |
| Regular Market Day High | 1.8 |
| Regular Market Day Low | 1.765 |
| Regular Market Day Range | 1.765 - 1.8 |
| Regular Market Open | 1.78 |
| Regular Market Previous Close | 1.76 |
| Regular Market Price | 1.78 |
| Regular Market Time | 1,784,037,316 |
| Regular Market Volume | 77,844 |
| Return On Assets | -0.81147003 |
| Return On Equity | -2.1468801 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 42,654,038 |
| Shares Percent Shares Out | 0.0846 |
| Shares Short | 3,608,175 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,198,541 |
| Short Name | Gain Therapeutics, Inc. |
| Short Percent Of Float | 0.0866 |
| Short Ratio | 2.79 |
| Source Interval | 15 |
| State | MD |
| Symbol | GANX |
| Target High Price | 8.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 7.2 |
| Target Median Price | 8.0 |
| Total Cash | 16,539,222 |
| Total Cash Per Share | 0.388 |
| Total Debt | 672,302 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.57 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.206725 |
| Two Hundred Day Average Change | -0.4267249 |
| Two Hundred Day Average Change Percent | -0.19337477 |
| Type Disp | Equity |
| Volume | 77,844 |
| Website | https://gaintherapeutics.com |
| Zip | 20,814 |